Immunomonitoring results of a pivotal phase II/III study with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in ovarian cancer patients with malignant ascites

M Jaeger,A. Schoberth,Markus M Heiss,A. Lähr,Horst Lindhofer

Immunomonitoring results of a pivotal phase II/III study with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in ovarian cancer patients with malignant ascites

2007

M Jaeger
A. Schoberth
Markus M Heiss
A. Lähr
Horst Lindhofer

3020 Background: Malignant ascites is a symptom of late-stage tumor disease and associated with a poor prognosis. The trifunctional antibody catumaxomab specifically binds to EpCAM+ tumor cells and...

Keywords:

Ovarian cancer
Catumaxomab
Trifunctional antibody
Immunology
Ascites
CD3
Medicine
Oncology
tumor cells
anti cd3
poor prognosis
Internal medicine
Disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations